Celanese Opens Pharmaceutical Drug Delivery Feasibility Lab at Florence, Kentucky Site

Rhea-AI Summary

Celanese Corporation (NYSE: CE) announced the expansion of its Florence, Kentucky R&D center with a new Pharmaceutical Drug Delivery Feasibility Lab. This expansion aims to enhance development for long-acting controlled release drug delivery, showcasing Celanese's commitment to its Pharmaceutical segment. The lab will provide services such as material characterization and prototyping capabilities, facilitating quicker project advancements for pharmaceutical companies. With over 40 years in the medical market, Celanese aims to innovate drug delivery solutions and improve patient health outcomes.

Positive

• Expansion of R&D capabilities with new lab enhances product offerings.
• Accelerates development for pharmaceutical companies, promoting faster market entry.

Negative

• None.

Celanese Corporation (NYSE: CE), a global chemical and specialty materials company, today announced an expansion of its Florence, Kentucky research and development center with the addition of a Pharmaceutical Drug Delivery Feasibility Lab. The new feasibility lab will drive new development for long-acting controlled release drug delivery. This represents a significant investment and commitment to the Pharmaceutical segment of Celanese’s engineered materials business. The feasibility lab expands pharmaceutical companies’ access to highly customized materials and service solutions.

The new Florence pharmaceutical feasibility lab enables Celanese to accelerate customers’ development projects for long-acting delivery of small molecules, biologics and RNA. Services include material characterization; injection molding, hot-melt extrusion, and other prototyping capabilities; monolithic or multi-layer drug-loaded prototypes; in vitro characterization and drug release studies; and tooling design and development.

“When Celanese works with pharmaceutical customers, we first seek to understand their design challenges and identify factors that are critical to quality,” noted Jeff Haley, Senior Manager and Product Specialist, Pharmaceutical Development for Celanese. “We then assemble the right team of experts, select the right tool set, and develop a program plan to help solve their materials challenges. Technical or materials requirements vary by customer, and Celanese is here to offer targeted solutions to ensure our customers can quickly bring to market a successful product that has a meaningful impact on patient health and quality of life.”

Celanese offers cutting-edge medical and pharmaceutical material solutions and expert development support to Medical Device and Pharmaceutical companies worldwide. With more than 40 years of experience supporting key applications and the demanding requirements of the medical market, Celanese is expanding design possibilities as our customers find new ways to deliver a sustained dose of medication over time. The Company’s continuously expanding Medical Technology® portfolio includes solutions and technologies for applications across drug delivery, medical devices, orthopedics, advanced surgical instruments and connected devices. For more information on healthcare-specific product features and benefits, visit: https://healthcare.celanese.com/products-and-solutions/vitaldose

Product Availability & Contacts

To discuss solutions for long-acting delivery of small molecules, biologics and RNA, contact a Celanese commercial representative via Healthcare@Celanese.com. To learn more about Celanese healthcare solutions, visit healthcare.celanese.com.

About Celanese

Celanese Corporation is a global chemical leader in the production of differentiated chemistry solutions and specialty materials used in most major industries and consumer applications. Our businesses use the full breadth of Celanese's global chemistry, technology and commercial expertise to create value for our customers, employees, shareholders and the corporation. As we partner with our customers to solve their most critical business needs, we strive to make a positive impact on our communities and the world through The Celanese Foundation. Based in Dallas, Celanese employs approximately 7,700 employees worldwide and had 2020 net sales of $5.7 billion. For more information about Celanese Corporation and its product offerings, visit www.celanese.com or our blog at www.celaneseblog.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005088/en/

FAQ

What is the new feasibility lab announced by Celanese on October 30, 2023?

Celanese announced a new Pharmaceutical Drug Delivery Feasibility Lab at its Florence, Kentucky R&D center to improve long-acting drug delivery solutions.

How will the new lab affect Celanese's pharmaceutical segment?

The new lab will enhance Celanese's capabilities in developing drug delivery systems, which is a significant investment in its pharmaceutical segment.

What services will the Pharmaceutical Drug Delivery Feasibility Lab offer?

The lab will provide services including material characterization, injection molding, hot-melt extrusion, and drug release studies for pharmaceutical companies.

When was the Celanese press release about the new lab issued?

The press release regarding the new Pharmaceutical Drug Delivery Feasibility Lab was issued on October 30, 2023.

What is the primary purpose of the new lab for pharmaceutical companies?

The primary purpose is to accelerate development projects for long-acting delivery of small molecules, biologics, and RNA.